ProPhase Labs and Advanced Biological Laboratories Announce Strategic Reverse Merger to Create Global Diagnostics Platform
核心洞察
ProPhase Labs (搜索) and Advanced Biological Laboratories (搜索) have signed a non-binding letter of intent for a reverse merger that would create a global diagnostics and genomics company with ABL owning approximately 76% of the combined entity.
The transaction includes significant shareholder benefits with a potential $10 million special cash dividend and approximately $50 million in Crown Medical Collections receivables carved out exclusively for current ProPhase shareholders.
The merger aims to accelerate global expansion of ProPhase's BE-Smart Esophageal Cancer Test and Nebula Genomics platform through ABL's international distribution network and regulatory expertise.
ProPhase Labs (搜索), Inc. (NASDAQ: PRPH) and Advanced Biological Laboratories (搜索) S.A. (ABL) announced December 19, 2025, that they have entered into a non-binding Letter of Intent regarding a proposed reverse merger transaction that would position ABL as the majority owner of the combined entity. The strategic combination aims to create a global platform for molecular diagnostics, genomics, and precision medicine technologies.
Transaction Structure and Valuation Framework
Under the preliminary terms outlined in the LOI, ABL shareholders would own approximately 76% of the combined company at closing. The parties have discussed a non-binding valuation framework for the legacy ProPhase business that may imply an enterprise value of up to approximately $30 million.
The transaction structure includes significant value preservation mechanisms for current ProPhase shareholders. ProPhase Labs (搜索) may declare a special cash dividend of up to $10 million payable to shareholders of record as of a date to be determined. This distribution would be separate from and not part of the merged operating company.
Additionally, all Crown Medical Collections receivables are expected to be carved out for the exclusive benefit of current ProPhase shareholders, with anticipated collections of approximately $50 million net. These estimates are subject to significant uncertainty, including collection risk and timing variability.
Strategic Rationale and Leadership Vision
"This LOI represents what we believe is one of the most important strategic developments in ProPhase Labs (搜索)' history," said Ted Karkus, Chief Executive Officer of ProPhase Labs. "The proposed transaction structure is designed to deliver meaningful near-term value to our existing shareholders, while aligning ProPhase within the ABL Group, a global leader in molecular analysis, clinical research, and healthcare innovation that can accelerate the development and long-term potential of our genomics and diagnostic programs."
Dr. Chalom B. Sayada, CEO of ABL, emphasized the strategic value for both organizations: "By combining with a Nasdaq-listed U.S. platform, ABL will gain enhanced access to U.S. capital markets and accelerate commercialization of its portfolio in the United States. At the same time, ABL's international distribution network and regulatory expertise will support global expansion of ProPhase's BE-Smart Esophageal Cancer Test, Nebula Genomics, and consumer health businesses."
Combined Platform and Technology Portfolio
Following completion of the merger, a newly established U.S. subsidiary would hold and operate ProPhase's key assets, including the Nebula Genomics platform, BE-Smart Esophageal Cancer Test program, and select consumer health businesses. This structure is designed to enable focused capital allocation and strategic execution under ProPhase's current management team.
ABL would contribute its global infrastructure, including advanced data processing systems, cloud computing capabilities for health data, and financing resources. The ABL Group operates through several successful subsidiaries:
- ABL Diagnostics (Euronext: ABLD, FR001400AHX6) delivers cutting-edge molecular testing solutions
- CDL Pharma provides clinical trial logistics and sample management services
- Humedics commercializes the LiMAx® liver function capacity test, a real-time breath test supporting liver surgery and transplantation
These companies would become sister entities to the new U.S. subsidiary, creating an integrated global platform for precision medicine and diagnostic innovation.
Financial Structure and Risk Allocation
The combined operating company would assume only those liabilities expressly agreed in definitive documentation, currently contemplated to include approximately $5 million of ProPhase Labs (搜索)' existing indebtedness. All other legacy liabilities would remain with ProPhase Labs and would not be obligations of the post-merger entity.
This liability allocation structure provides additional protection for the combined entity's financial position while ensuring current ProPhase shareholders retain access to the carved-out assets and potential distributions.
Transaction Timeline and Regulatory Requirements
The LOI reflects preliminary understandings only and does not create any obligation to consummate a transaction, except with respect to customary confidentiality and expense provisions. The parties currently anticipate working toward execution of definitive documentation within approximately 60 to 90 days.
The proposed transaction remains subject to completion of due diligence, negotiation and execution of definitive agreements, regulatory approvals, Nasdaq listing requirements, and other customary closing conditions. There can be no assurance that a definitive agreement will be reached or that the transaction will be consummated.
The transaction framework is subject to change based on due diligence findings, capitalization adjustments, financing activity, market conditions, and final transaction terms. Both companies have emphasized that the preliminary structure expressly excludes certain cash distributions, asset carve-outs, and retained liabilities that will be detailed in definitive documentation.